Pandorum Technologies Raises USD 18 Million in Series B to Advance Regenerative Therapies
Pandorum Technologies has raised USD 18 million in a Series B funding round to accelerate the clinical development and global market access of its programmable tissue regenerative therapies, with expansion plans spanning the US, Asia and the Middle East.
Galentic Pharma | 11/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy